Literature DB >> 19373416

Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data?

Paul Moayyedi, Daniel C Sadowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19373416      PMCID： PMC2711671          DOI： 10.1155/2009/868946

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  12 in total

1.  ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

Authors:  Deepak L Bhatt; James Scheiman; Neena S Abraham; Elliott M Antman; Francis K L Chan; Curt D Furberg; David A Johnson; Kenneth W Mahaffey; Eamonn M Quigley
Journal:  Circulation       Date:  2008-10-03       Impact factor: 29.690

Review 2.  Pharmacogenetics of the proton pump inhibitors: a systematic review.

Authors:  Elaine Chong; Mary H H Ensom
Journal:  Pharmacotherapy       Date:  2003-04       Impact factor: 4.705

3.  Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Authors:  Francis K L Chan; Jessica Y L Ching; Lawrence C T Hung; Vincent W S Wong; Vincent K S Leung; Nelson N S Kung; Aric J Hui; Justin C Y Wu; Wai K Leung; Vivian W Y Lee; Kenneth K C Lee; Yuk T Lee; James Y W Lau; Ka F To; Henry L Y Chan; S C Sydney Chung; Joseph J Y Sung
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.

Authors:  David N Juurlink; Tara Gomes; Dennis T Ko; Paul E Szmitko; Peter C Austin; Jack V Tu; David A Henry; Alex Kopp; Muhammad M Mamdani
Journal:  CMAJ       Date:  2009-01-28       Impact factor: 8.262

5.  Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

Authors:  Xue-Qing Li; Tommy B Andersson; Marie Ahlström; Lars Weidolf
Journal:  Drug Metab Dispos       Date:  2004-08       Impact factor: 3.922

6.  Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

Authors:  Martine Gilard; Bertrand Arnaud; Jean-Christophe Cornily; Grégoire Le Gal; Karine Lacut; Geneviève Le Calvez; Jacques Mansourati; Dominique Mottier; Jean-François Abgrall; Jacques Boschat
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.

Authors:  A Rostom; P Moayyedi; R Hunt
Journal:  Aliment Pharmacol Ther       Date:  2008-11-27       Impact factor: 8.171

9.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

10.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690
View more
  4 in total

Review 1.  The risks of PPI therapy.

Authors:  Paul Moayyedi; Grigorios I Leontiadis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-14       Impact factor: 46.802

2.  What you need to know when you prescribe a proton pump inhibitor.

Authors:  A Norman; C J Hawkey
Journal:  Frontline Gastroenterol       Date:  2011-06-24

Review 3.  Diagnosis and therapy of non-variceal upper gastrointestinal bleeding.

Authors:  Erwin Biecker
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

4.  Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding.

Authors:  Qing Wang; Rickard Ljung; Jesper Lagergren; Yunxia Lu
Journal:  BMC Pharmacol Toxicol       Date:  2014-04-15       Impact factor: 2.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.